PTAB: Petitioner Not Obliged to Address Evidence of Object Indicia That is Neither Tethered to the Claim nor Previously Found Persuasive

Mar 5, 2021

Reading Time : 2 min

The petitioner challenged claims of a patent whose parent had been challenged previously in an IPR by a third party. In that earlier proceeding, the board found that all of the parent patent’s claims were unpatentable for obviousness, despite the patent owner’s attempt to show nonobviousness by submitting evidence of objective indicia.

In the IPR challenging the claims of the child patent, the patent owner argued in its preliminary response that the petitioner should have addressed objective indicia evidence that was present in the specification. The board’s institution decision “did not expressly address” that argument. Following institution, the patent owner sought rehearing, arguing in part that the board had erred by overlooking the objective indicia evidence, and that the petition was “facially deficient” because it did not address the evidence present in the specification and original prosecution history.

The board rejected the patent owner’s contention that the board had erred. First, the board explained that the child patent did “not have an extensive litigation record of objective indicia supporting nonobviousness” and so case law requiring a petitioner to address such evidence was inapposite. Rather, in the IPR proceeding challenging the parent patent, the board had found that patent owner’s objective indicia evidence did not establish nonobviousness. Second, the board explained that the objective indicia evidence concerned a limitation that was not present in the challenged claims. As such, for either of those reasons, the petitioner did not have to address the evidence in the petition. The board further explained that to the extent the patent owner had submitted additional evidence on this issue, the petitioner had not yet had an opportunity to respond, and so the record could be developed during trial.

The board completed its analysis by turning to the merits of the patent owner’s evidence at the institution stage. The board found that the patent owner had made only “generalized arguments” and had not presented “sufficient factual evidence” to establish its allegations of unexpected results in support of nonobviousness. In conclusion, the board denied the request for rehearing for failing to show the board had abused its discretion in instituting the IPR.

Practice Tip: Both sides in America Invents Act (AIA) proceedings should carefully consider whether evidence of objective indicia that is relevant to the challenged claims has been fully developed in prior proceedings, such as during prosecution, reexamination, an AIA trial, an International Trade Commission (ITC) investigation or a district court litigation. A petitioner may need to address objective evidence of nonobviousness or risk denial of institution if the patent owner successfully argues that the evidence ought to have been addressed in the petition. Conversely, in the absence of a fully developed record of objective indicia evidence, a petitioner may not be obliged to address that evidence, and a patent owner may be better served by attacking the petition in other ways.

Liquidia Techs., Inc. v. United Therapeutics Corp., IPR2020-00770, Paper 14 (PTAB Mar. 1, 2021)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.